PMID- 28399097
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20181202
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 117
IP  - 3
DP  - 2017
TI  - [Influence chronopharmacology therapy methionine (melaxen) on the dynamics of 
      sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic 
      factor (BDNF) in patients with cerebral stroke in the early and late recovery 
      periods].
PG  - 56-64
LID - 10.17116/jnevro20171173156-64 [doi]
AB  - AIM: To study the efficacy of melaxen on the dynamics of sleep disturbance, 
      cognitive and emotional disorders, BDNF and the level of secretion of melatonin 
      (6-SOMT) in patients with stroke in the early and late recovery phase. MATERIAL 
      AND METHODS: One hundred and ten patients in the rehabilitation period of stroke 
      (mean age of 58.4+/-6.4 years), including 60 patients in the early recovery phase 
      (group 1) and 50 patients in the late phase (group 2), were studied. Patients 
      received melaxen in dose of 3 mg/day for 3 months along with standard treatment. 
      The efficacy of therapy was assessed by the dynamics of sleep disorders, 
      emotional status, dynamics of serum BDNF levels, 6-SOMT concentration in the 
      urine. RESULTS AND CONCLUSION: The study has demonstrated the high efficacy of 
      melaxen in the rehabilitation of patients in early and late recovery phase of 
      stroke. The drug significantly increased the BDNF level that correlated with 
      improved sleep, emotional status, quality of life of patients.
FAU - Kostenko, E V
AU  - Kostenko EV
AD  - Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative 
      and Sports Medicine of Moscow Healthcare Department, Moscow, Russia, Pirogov 
      Russian National Research Medical University, Moscow, Russia.
LA  - rus
PT  - Journal Article
TT  - Vliianie khronofarmakologicheskoi terapii melatoninom (melaksen) na dinamiku 
      narushenii sna, kognitivnykh i emotsional'nykh rasstroistv, neirotroficheskogo 
      faktora mozga u patsientov v vosstanovitel'nom periode insul'ta.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - JL5DK93RCL (Melatonin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cognition Disorders/blood/*drug therapy/etiology
MH  - *Drug Chronotherapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Melatonin/*administration & dosage
MH  - Middle Aged
MH  - Mood Disorders/blood/*drug therapy/etiology
MH  - Quality of Life
MH  - Sleep Wake Disorders/blood/*drug therapy/etiology
MH  - Stroke/blood/*complications
MH  - *Stroke Rehabilitation
EDAT- 2017/04/12 06:00
MHDA- 2017/08/15 06:00
CRDT- 2017/04/12 06:00
PHST- 2017/04/12 06:00 [entrez]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
AID - 10.17116/jnevro20171173156-64 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3):56-64. doi: 
      10.17116/jnevro20171173156-64.